A new drug in development called “CCS1477” which is for the treatment of patients with late stage prostate cancer.

What’s this all about and who could benefit?

CCS1477 is expected to be offered to advanced prostate cancer patients if the prostate cancer starts to show signs of resistance to the existing hormone therapy drugs, abiraterone (Zytiga) and enzalutamide (Xtandi).

Who is developing CCS1477?

This drug is being developed by CellCentric, a Cambridge-based biotechnology company.

The company was set up to explore a new area of science called ‘epigenetics’. Epigenetics looks at changes to how our body reads the building blocks of life, DNA, and how these changes can turn certain genes “on” and “off”. Sometimes these changes go wrong and as a result diseases such as cancer can develop.

What has CellCentric discovered so far?

Previous research has shown that the androgen receptor is a key driver in tumour growth in prostate cancer. CellCentric has worked on making epigenetic changes to the androgen receptor gene. They have developed a method to target the androgen receptor in order to control its activity.

How does CCS1477 work exactly?

CellCentric’s new drug CCS1477 is the first of its kind. It works by blocking the effects of two key proteins, p300 and CBP, which control cancer genes. These proteins work together to switch on prostate cancer genes involved in cancer progression, including the androgen receptor genes. By blocking these proteins, CCS1477 reduces the activity of the androgen receptor and this slows the growth of prostate cancer.

At what stage of development is CCS1477?

CCS1477 began Phase 1/2 clinical trials in 2018. In these trials CellCentric has been working to determine a suitable dosage for CCS1477 that is both safe and effective, and has enrolled many prostate cancer patients through various cancer centres in the UK.  Their clinical trials will continue to expand in the UK as well as in the EU and USA, and their aim is to hopefully begin Phase 3 trials sometime within the next 1-2 years.

One of the main issues the current clinical trials will focus on is whether combining CCS1477 with the existing hormone therapy drugs, abiraterone (Zytiga) and enzalutamide (Xtandi), will result in a more prolonged response and delay or even prevent the development of hormone therapy resistance.

Where can I find more information?

Further information about CCS1477 can also be found on CellCentric’s website

To find out more about how clinical trials work, including the various stages and typical timelines, please click here.

If you want to hear more about CCS1477 you can listen to an episode of our new podcast, The Prostate Pod, where we talk with the CEO of CellCentric about epigenetics, CCS1477 and more!

 

Get updates!

If you are interested in hearing updates about CCS1477’s development journey please fill out your details below and we will be sure to update you when we have news. This information will not be used for any purpose other than providing you updates on CCS1477 and will not be shared outside our organisation.

* indicates required